Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevo dispositivo de diagnóstico y tratamiento de enfermedades oculares


Oferta Tecnológica
Un grupo de instituciones de salud pública de Singapur ha desarrollado un dispositivo que simultáneamente inyecta agentes terapéuticos en el ojo y extrae muestras vítreas del ojo para análisis de biomarcadores de las enfermedades de degeneración macular relacionada con la edad y retinopatía diabética. El objetivo es reducir el número de inyecciones en el ojo y realizar tratamientos personalizados en función del estado del paciente, reduciendo las visitas y tratamientos innecesarios y ahorrando costes. El grupo busca pymes, multinacionales, universidades e instituciones de I+D con el fin de establecer acuerdos de licencia y joint venture.


A novel diagnostic-therapeutic device for the eye
A Singapore group of public healthcare institutions has developed a device that simultaneously injects therapeutic agents into the eye and extracts vitreous samples from the eye for biomarker analysis of age-related macular degeneration (AMD) and diabetic retinopathy (DR) diseases.

The group is seeking commercialization partnerships with SMEs of any sizes, MNEs, universities or R-Y-D institutions with interests to explore a license agreement or a joint venture for this device.
Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are the leading causes of blindness in elderly patients worldwide. Over the past decade, anti-vascular endothelial growth factor (anti-VEGF) agents are injected directly into the posterior segment of the eye, and it is the standard of care for AMD/DR.

More than 10,000 injections/year are performed locally in a Singapore hospital. The current evidence for AMD/DR suggests that the administration of intravitreal injections of anti-VEGF agents shows good treatment outcomes. However, the injections are uncomfortable and difficult for patients to comply to.

Moreover, the ocular and systemic safety of these repeated injections over long periods of time are unclear. Currently, clinical trial treatment regimens (monthly injections for 1-2 years) are difficult to replicate in real clinical settings.

The device being offered by the Singapore healthcare group is designed to simultaneously extract vitreous samples for the measurement of biomarkers and inject therapeutics into the same device. This integrated design aims to reduce the number of injections to the eye, allowing tailored treatments based on the patient´s current condition, and reduces unnecessary treatments and visits, resulting in cost savings by patients.

A functional design for the device has been established, which provides a combination of suction for the biopsy extraction, and subsequent therapeutic injection. The device is able to deliver therapeutics accurately and safely by removing a sample first to prevent an acute spike in IOP and reducing drug reflux from the eye. It acquires biopsy samples safely as the design ensures that vitreous traction is minimised by the duel needle mechanism. Suction is first applied by a large bore needle and a smaller bore needle moves forward within the larger bore needle, shaving off vitreous traction and separating the sample collected. Therapeutics are then administered through the smaller bore needle which is within the larger bore needle at this point.

The injection mechanism is currently an adapted 1 ml syringe. In addition, only a small amount of material is necessary for sample measurement. Measuring vitreous biomarkers may provide clinicians with the ability to treat conditions before they cause functional damage and also to move away from protocol-driven treatment regimens. It also paves a way for biomarker discovery in research.

The Singapore healthcare group is seeking to commercialize the technology to global industry partners such as SMEs of any sizes, MNEs, universities or R-Y-D institutions that are interested to explore the following:

- License agreement
- Joint venture agreement
Advantages and Innovations:
This technology will be applicable to ocular syringe suppliers and ocular drug manufacturers. There are no direct competitors in the market that provide simultaneous biopsy and therapeutic injection capabilities.

Current methods for obtaining a vitreous biopsy use standard needle and syringe systems which are not purpose-built for obtaining samples and have a high risk of complications. Hence the procedure is reserved for eye conditions where the clinical need for biopsy is deemed to outweigh the risk of complications such as retinal detachment and bleeding. These biopsies are not done routinely in eyes with age-related macular degeneration (AMD) and diabetic retinopathy (DR).

The proposed solution is a device specifically designed for the eye with safety and ergonomic features. The other advantages include:
- reduction of frequent unnecessary injections,
- low risk of damage to intra-ocular structures, retinal detachment
and vitreal hemorrhage
- the device has the potential to deliver a wide range of drugs with the use of standard syringe fittings.

Monitoring VEGF or anti-VEGF agent levels from extracted fluids as a biomarker to determine specific dosage and injection frequency enables individualised and patient-tailored therapy.
Stage of Development:
Prototype available for demonstration
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The types of partners sought include:
- SMEs of any sizes
- University
- Inventor
- R-Y-D Institution

The types of partnerships considered include:
- Joint venture agreement
- License agreement

The role of the partner would be to either commercialize the technology to bring to market or to further develop this technology to meet the demand-driven needs of the addressable market.


Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
01004001 Applications for Health
06001005 Diagnósticos, diagnosis
06001012 Investigaciones médicas
06001013 Tecnología médica / ingeniería biomédica